{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_names_stdName in (root_names_stdName (approximate match)
Status:
Investigational
Source:
NCT00751803: Phase 2 Interventional Completed Migraine Disorders
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
BI 44370 was developed as a calcitonin gene-related peptide receptor antagonist for the treatment of acute migraine attacks. In spite of the positive results from the phase II clinical trials, the BI-44370 study has been discontinued.
Status:
Investigational
Source:
NCT00682123: Phase 1/Phase 2 Interventional Completed Positive Doping Tests in Sports
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00166543: Phase 2 Interventional Completed Breast Cancer
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
TAS-108 (also known as SR-16234) is a selective estrogen receptor modulator (SERM) and has been reported to have estrogen receptor (ER) α antagonistic activity and a strong affinity with a weak partial agonistic activity to ERβ receptor. It is known that ERs play a central role in the diverse actions of estrogen. TAS-108 was studied in phase II clinical trials to treat recurrent or recurrent inoperable breast cancer. In addition, TAS-108 participated in Japan in a phase II clinical trial in Endometriosis patients. The phase III studies are being planned with the drug.
Status:
Investigational
Source:
INN:quilseconazole [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
Front Immunol. 2019;10:1275.: Not Applicable Human clinical trial Completed Psoriasis/blood/immunology
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02490891: Phase 2 Interventional Unknown status Lymphoma
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
FLOTEGATIDE is a cyclic tripeptide with arginine-glycine-aspartic acid (R-G-D) motif. Its 18F radiolabelled form is a positron emission tomography (PET) tracer targeting integrin alpha-V/beta-3.
Status:
Investigational
Source:
NCT03847467: Phase 1/Phase 2 Interventional Recruiting Inflammatory Bowel Diseases
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01300026: Phase 1 Interventional Completed Cancer
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
AMG-319 is an oral, small molecule inhibitor of PI3Kdelta which is now being tested in phase II for the treatment of head and neck squamous cell carcinoma and in phase I for lymphoid malignancy.
Status:
Investigational
Source:
NCT00357357: Phase 2 Interventional Completed Alzheimer's Disease
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02684591: Phase 2 Interventional Completed Nonalcoholic Fatty Liver Disease
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
